Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Corbus Pharmaceuticals: Down But Not Out
04:59am, Friday, 29'th Jan 2021
Major disappointment last year due to lenabasum not meeting its endpoints in a phase 3 and phase 2 trial. Massive expectation meant that the company had to downsize significantly to keep operations go
Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma
Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3%
09:02am, Thursday, 14'th Jan 2021
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options
09:47am, Tuesday, 12'th Jan 2021
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharma: 8 Things for CRBP Stock Investors to Know About the Company
11:37am, Tuesday, 01'st Dec 2020
Corbus Pharma (CRBP) is seeing massive gains for CRBP stock on Tuesday despite a lack of recent news from the pharmaceuticals company. The post Corbus Pharma: 8 Things for CRBP Stock Investors to Know
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q3 2020 Results - Earnings Call Transcript
01:53pm, Tuesday, 10'th Nov 2020
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q3 2020 Results - Earnings Call Transcript
Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) CEO Yuval Cohen On Q3 2020 Results - Quick Version Earnings Call Transcript
09:54am, Tuesday, 10'th Nov 2020
Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) CEO Yuval Cohen On Q3 2020 Results - Quick Version Earnings Call Transcript
Corbus Pharmaceuticals: Q3 Earnings Insights
07:32am, Tuesday, 10'th Nov 2020
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 34.37% year over year to ($0.43), w
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
07:05am, Tuesday, 10'th Nov 2020
Norwood, MA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma
Corbus Pharmaceuticals's Earnings: A Preview
10:27am, Monday, 09'th Nov 2020
On Tuesday, November 10, Corbus Pharmaceuticals (NASDAQ: CRBP) will release its latest earnings report. Benzinga's outlook for Corbus Pharmaceuticals is included in the following report.
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
08:05am, Monday, 09'th Nov 2020
Norwood, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
08:05am, Tuesday, 03'rd Nov 2020
Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma
Corbus Pharmaceuticals: Ultra High Implied Volatility Brings Opportunity
12:49pm, Friday, 21'st Aug 2020
Many speculators are looking at the potential upside in here. We are focusing more on the pending volatility crush.
3 Stocks Robinhood Investors Love
12:15pm, Sunday, 16'th Aug 2020
Robinhood, a free app offering commission-free trading of stocks, options, and more, has attracted a lot of attention in recent months. Among Robinhood's 100 most popular stocks, the highest-rated ac
Looking Into Corbus Pharmaceuticals's Return On Capital Employed
02:31pm, Friday, 14'th Aug 2020
In Q2, Corbus Pharmaceuticals (NASDAQ: CRBP) posted sales of $286.35 thousand. Earnings were up 27.62%, but Corbus Pharmaceuticals still reported an overall loss of $38.14 million. Corbus Pharmaceutic
